SCENESSE® Granted Market Access In Israel
CLINUVEL today announced that SCENESSE® (afamelanotide 16mg) has been added to the...
Read More
SCENESSE® DNA REPAIR STUDY IN HEALTHY VOLUNTEERS APPROVED
Melbourne, Australia, 30 November 2020 CLINUVEL PHARMACEUTICALS LTD today announced that it...
Read More
Afamelanotide for Acute Stroke Patients
EXECUTIVE SUMMARY • World’s first pilot study (CUV801) to evaluate afamelanotide in...
Read More
Media Release – CLINUVEL to Trial Innovative Drug in Stroke
The drug afamelanotide will be used for the first time in patients...
Read More
Update: SCENESSE® in DNA Repair
CLINUVEL PHARMACEUTICALS LTD provided today a clinical update on the use of...
Read More
Media Release - First patient dosed in SCENESSE® DNA Repair Program
Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment In the search for a...
Read More
First patient dosed in SCENESSE® DNA Repair Program
Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment CLINUVEL PHARMACEUTICALS LTD today announced...
Read More
Media Release (ASX) - CLINUVEL progresses innovative DNA Repair Program
Drug tested to protect skin and regenerate DNA, firstly in XP patients...
Read More
Media Release – New drug to repair damaged skin and reduce skin cancer risk
Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with...
Read More
SCENESSE® in DNA Repair
CLINUVEL to confirm cellular DNA repair in rare disease xeroderma pigmentosum (XP)...
Read More
Media Release - Second Afamelanotide Formulation
PRÉNUMBRA®- CLINUVEL’S SECOND AFAMELANOTIDE FORMULATION Drug to be evaluated in patients with...
Read More
PRÉNUMBRA® – New Liquid Afamelanotide Presentation
EXECUTIVE SUMMARY • PRÉNUMBRA® non-solid dosage form of afamelanotide • Active life-cycle...
Read More